2016 went out like a lamb in the biopharma M&A world. Will it roar back in 2017? Plus, top 10 deals
Dealmakers evidently spent the fourth quarter of 2016 largely in hibernation as they waited out a big US election cycle that seemed to raise more questions than it answered.
In a look back over a relatively quiet year, EP Vantage, the editorial arm at Evaluate, concluded that 2016 may not have ended anywhere close to any of the records set during the boom, but I would add that the numbers reflect some considerable financial muscle that could be flexed in the year to come.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
